Future Oncology

Papers
(The H4-Index of Future Oncology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
A Concise Prognostic Score System for Diffuse Large B-Cell Lymphoma: A Retrospective Study with Long-Term Follow-Up122
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes91
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma79
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study65
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer55
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression52
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice45
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis45
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe45
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer43
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib42
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma41
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites41
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)41
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study40
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer40
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?39
Sex bias phenomenon in oral cancer: an insight38
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma38
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil37
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression37
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study36
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study35
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges34
Development and Validation of An Immune Gene Set-Based Prognostic Signature in Cutaneous Melanoma31
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?31
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges30
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)30
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis30
Is Obesity a Risk Factor in Cancer Patients with COVID-19?29
0.12896490097046